more

Related Articles

Novo Grabs Xellia Pharma for $700M
Actavis to Buy Warner Chilcott To Expand in Women’s Health
Alliant, Bellisio Foods, TransDigm
Aridis Pharma Picks Up Kenta Biotech’s Anti-Infection Products
Bayer Buys Herbal Medicine Maker

SLIDESHOW

The M&A Scene: CEO Leadership
Dealmakers gathered at the Harvard Club in New York on May 7 as part of ACG NY's CEO Leadership event. Peter Gonye, a co-leader within Spencer Stuart's private equity practice in North America was the keynote speaker. Panelists included M. Tatum Pursell, senior adviser, Unlimited Horizons; Tony Ecock, general partner, Welsh Carson Anderson & Stowe; Jim Follett, former CEO of Authentic Response Inc.; Doron Grosman, operating partner, Court Square Capital; and Joelle Marquis, partner, Arsenal Capital.

Watercooler

Far Cry from the Glory Days
These days, big buyers are more likely to co-invest with limited partners

Dealmakers

Time Inc. -Meredith Pairing Would Have Been Too Complicated, Says Jeff Bewkes in Keynote
The Time Warner chairman hints there may be a future deal for the spun-off magazine business, maybe even with Meredith

Columns

The Buyside:
Trench Dealfare
Strategic players in the aerospace and defense sector look to offset losses by remaining on the hunt for targets

Today's Transactions:
Pernix Therapeutics Buys Cypress and Hawthorn Pharmaceuticals for $101M

Cypress produces generic medication and Hawthorn makes branded medication

By ALLISON COLLINS
November 14, 2012

Pernix Therapeutics Holdings Inc. (NYSE: PTX) will purchase Cypress Pharmaceutical Inc., a privately-held company that makes generic pharmaceuticals, and Hawthorn Pharmaceuticals Inc., a company that makes branded pharmaceuticals for up to $101 million.

The buyer, a specialty pharmaceutical company based in the Woodlands, Texas, will make an upfront payment of $68.5 million in cash and $12.5 million in equity. The company has a $60 million credit facility arranged by MidCap Financial.

Both targets are headquartered in Madison, Miss., and combined have about $50 million in revenue.

Pernix expects the deal to increase its branded and generic portfolio. The deal is subject to regulatory approval.

 

For more information on related topics, visit the following: